What happens when a biotech company realises that its next stage of growth requires a completely different approach?

In this episode of She Leads Biotech, I'm joined by Beverley Carr, Chief Business and Operating Officer at CHARM Therapeutics, to explore the realities of transforming promising science into a clinical-stage business.

Beverley shares the decisions behind CHARM's shift from a broad AI drug discovery platform to a focused oncology programme, the challenges of restructuring a business for its next stage, and why having the right people in place matters just as much as having great science.

We also discuss the real value of AI in drug discovery, the importance of making difficult decisions early, and Beverley's own journey from chemistry to biotech leadership.

It's a conversation about adaptability, courage and recognising when the path forward requires doing things differently.

Because sometimes the most important leadership decision isn't what to pursue next, but what you're prepared to leave behind.

🎧 Listen now on She Leads Biotech.

#SheLeadsBiotech #BiotechLeadership #WomenInBiotech #DrugDiscovery #LifeSciences

How much do we really understand about our own health, and how often have we been told that symptoms are simply "normal"?

In this episode, I'm joined by Paula Soteropoulos, biotech executive and investor, and her daughter Dr. Alexia Soteropoulos, an integrative and functional medicine physician, to discuss their book Restoring Balance and why women need to take a more active role in understanding their bodies.

We explore the gaps in women's health research, menopause, hormone health, whole-person care and the importance of questioning symptoms that are too often dismissed or normalised.

Paula brings her perspective from biotech leadership and investment, while Alexia shares her clinical approach to helping women become better informed advocates for their own health.

A warm, thought-provoking conversation about knowledge, self-advocacy and restoring balance to women's healthcare.

What if the biggest challenge in biotech isn't innovation, but adoption?

I'm joined by Holley Miller, CEO of Grey Matter Marketing, to explore why better science doesn't automatically win.

We talk about why people buy outcomes rather than products, why emotion can open the door before data earns belief, the importance of solving an urgent problem, and why being different can sometimes matter more than simply being better.

Holley also shares her own entrepreneurial and leadership journey, the value of non-obvious thinking, taking career risks and giving yourself permission to fail.

A thought-provoking conversation about innovation, human behaviour and what it really takes to turn a great idea into something people will actually adopt.